adamantane has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, DL; Bonaca, MP; Braunwald, E; Gutierrez, JA; Hirshberg, B; Im, K; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Gross, GJ; Nithipatikom, K | 1 |
1 review(s) available for adamantane and Coronary Disease
| Article | Year |
|---|---|
Soluble epoxide hydrolase: a new target for cardioprotection.
Topics: Adamantane; Animals; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Dose-Response Relationship, Drug; Drug Design; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Arrest; Humans; Lauric Acids; Mice; Mice, Knockout; Myocardial Contraction; Myocardial Infarction; Urea | 2009 |
1 trial(s) available for adamantane and Coronary Disease
| Article | Year |
|---|---|
Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
Topics: Adamantane; Aged; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Prevalence; Risk Factors; Treatment Outcome | 2019 |